E. van Twuijver

Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults

M. Hohenboken, Daphne C Sawlwin, E. Versage, 2021, Vaccines.

A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations

R. Van Ree, L. Klimek, O. Pfaar, 2014, Clinical and Translational Allergy.

Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.

P. Chanthavanich, M. Hohenboken, E. Versage, 2021, Vaccine.

Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Grass Pollen Preparation

R. Van Ree, L. Klimek, O. Pfaar, 2012, International Archives of Allergy and Immunology.

A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT‐birch pollen extract for the treatment of allergic rhinitis: results of a phase II study

R. Van Ree, P. Kuna, O. Pfaar, 2015, Allergy.

Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects

M. Hohenboken, James T Peterson, E. Versage, 2022, Vaccines.

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions

M. Hohenboken, E. van Twuijver, Tino F. Schwarz, 2024, Vaccines.

Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults

Sharon Frey, M. Hohenboken, E. van Twuijver, 2023, Human vaccines & immunotherapeutics.